Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H.
Jabbour E, et al. Among authors: hunter am.
JAMA Oncol. 2024 Nov 21:e245157. doi: 10.1001/jamaoncol.2024.5157. Online ahead of print.
JAMA Oncol. 2024.
PMID: 39570620